Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

Yasushi Miyazakia (Lead / Corresponding author), Sudhir Tauro

Research output: Contribution to journalArticle

1 Citation (Scopus)
105 Downloads (Pure)

Abstract

Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5,838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.
Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalLeukemia Research
Volume73
Early online date6 Sep 2018
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Myelodysplastic Syndromes
Cytogenetics
Survival
Intrinsic Factor
Acute Myeloid Leukemia
Leukemia
Databases
Diet

Keywords

  • Clinical features
  • Ethnicity
  • Karyotype
  • Myelodysplastic syndromes
  • Survival

Cite this

@article{af15a1995b93469ea7adc0129a74e25e,
title = "Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS",
abstract = "Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5,838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.",
keywords = "Clinical features, Ethnicity, Karyotype, Myelodysplastic syndromes, Survival",
author = "Yasushi Miyazakia and Sudhir Tauro",
note = "This work was in part supported by the MDS Foundation, Inc, and the National Research Group on Idiopathic Bone Marrow Failure Syndromes, granted by the Ministry of Health, Labor and Welfare, Japan (H26-NanchiIppan-062, and H29-Nanchi-Ippan-026).",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.leukres.2018.08.022",
language = "English",
volume = "73",
pages = "51--57",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier",

}

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes : Analysis from the International Working Group for Prognosis of MDS. / Miyazakia, Yasushi (Lead / Corresponding author); Tauro, Sudhir.

In: Leukemia Research, Vol. 73, 01.10.2018, p. 51-57.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes

T2 - Analysis from the International Working Group for Prognosis of MDS

AU - Miyazakia, Yasushi

AU - Tauro, Sudhir

N1 - This work was in part supported by the MDS Foundation, Inc, and the National Research Group on Idiopathic Bone Marrow Failure Syndromes, granted by the Ministry of Health, Labor and Welfare, Japan (H26-NanchiIppan-062, and H29-Nanchi-Ippan-026).

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5,838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.

AB - Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5,838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.

KW - Clinical features

KW - Ethnicity

KW - Karyotype

KW - Myelodysplastic syndromes

KW - Survival

U2 - 10.1016/j.leukres.2018.08.022

DO - 10.1016/j.leukres.2018.08.022

M3 - Article

C2 - 30219650

VL - 73

SP - 51

EP - 57

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -